Close Menu

NEW YORK – Lucira Health, a startup formerly known as Diassess, announced today it has closed a $15 million Series B equity financing round.

The Emeryville, California-based developer of instrument-free, molecular diagnostics for infectious disease testing intends to use the funds to finance regulatory clearances and early commercialization.

The funding was led by Seraph Group with participation from Eclipse Ventures, DCVC (Data Collective), Y Combinator, Sunstone Management, and ShangBay Capital, the firm said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.